article thumbnail

UK agency pilots biobank to study links between genetics and drug side effects

Pharmaceutical Technology

The Medicines and Healthcare products Regulatory Agency (MHRA) aims to launch a pilot genetic biobank that will gather patient data to associate drug-related adverse events to their genetic makeup. The Yellow Card biobank will launch as a joint venture with the UK-government funded entity Genomics England on June 1.

article thumbnail

UK Agency targets blood thinners in personalised medicine pursuit

Pharmaceutical Technology

The MHRA kicks off phase two of the Yellow Card biobank to explore the genetic link to side effects of direct oral anticoagulants.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Poor sleep may bolster genetic susceptibility to asthma, potentially doubling risk

Medical Xpress

Poor quality sleep may bolster a person's genetic susceptibility to asthma, potentially doubling their risk of being diagnosed with the condition, suggests a large UK Biobank study, published in BMJ Open Respiratory Research.

article thumbnail

Ten new genetic loci linked to osteoarthritis found

Medical Xpress

A team of researchers affiliated with several institutions in Alabama has linked 10 genetic loci to the development of osteoarthritis. In their paper published in the journal Nature Genetics, the group describes their analysis of data from the Million Veteran Program in the U.S. and the UK Biobank in the U.K.

article thumbnail

Alnylam finds belly fat gene and drug target in UK Biobank study

pharmaphorum

. “We are currently testing this hypothesis, with the goal of pursuing a development candidate targeting INHBE in the near future,” said Paul Nioi, head of Alnylam’s human genetics group. The post Alnylam finds belly fat gene and drug target in UK Biobank study appeared first on.

article thumbnail

Could genetics hold the key to preventing SIDS?

Scienmag

Credit: Unsplash A state-of-the-art genetic biobank could hold the key to preventing Sudden Infant Death Syndrome (SIDS), potentially saving the lives of hundreds of babies who die from the devastating condition each year.

article thumbnail

Can genetic data be a magic bullet for drug R&D?

pharmaphorum

Ben Hargreaves finds that the vast amount of genetic data that exists today could help provide a faster, more targeted way of developing new drug candidates. The logical extension to this kind of approach is treating individual patients, with their individual genetic makeup.